ViroPharma Earnings: Here’s Why Investors are Not Happy Now

  Google+ | + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

ViroPharma Inc. (NASDAQ:VPHM) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are down 3.87%.

These stocks are hitting our Profit Targets. Click here now to discover winning stocks!

ViroPharma Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share decreased 81.13% to $0.10 in the quarter versus EPS of $0.53 in the year-earlier quarter.

Revenue: Decreased 26.84% to $106.5 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: ViroPharma Inc. reported adjusted EPS income of $0.10 per share. By that measure, the company beat the mean analyst estimate of $0.03. It beat the average revenue estimate of $103.06 million.

Quoting Management: “ViroPharma enters 2013 in a strong position to generate significant growth for years to come,” stated Vincent Milano, ViroPharma’s chief executive officer. “Cinryze in the U.S. continues to exceed our expectations, our products in Europe are beginning to demonstrate traction as we continue to expand those launches throughout the EU, the pipeline is more robust than it has ever been in our company’s history and financially our company is in a very good position to remain opportunistic for the right business development assets. Additionally, we’ve very aggressively improved our capital structure through our stock repurchase program. In 2013, our focus will remain on execution and continuing to deliver positive results to all of our key stakeholders and most importantly those that are at the core of our mission, the patients.”

Key Stats (on next page)…

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business